Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2025-4575

Published: 2025

Journal Articles

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

Blood (2025) 146 (Supplement 1): 5850.

https://doi.org/10.1182/blood-2025-5850

Published: 2025

Journal Articles

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

Blood (2025) 146 (Supplement 1): 5834.

https://doi.org/10.1182/blood-2025-5834

Published: 2025

Journal Articles

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia

Anath Lionel, Lorenzo Gensini, Sherif Seif, Wenli Dong, Lei Feng, Janelle Sanchez, Hima Bansal, Melody Becnel, Mahmoud Gaballa, Hans Lee, Oren Pasvolsky, Krina Patel, Jing Christine Ye, Keyur Patel, Donna Weber, Robert Orlowski, Sheeba Thomas

Blood (2025) 146 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2025-1829

Published: 2025

Journal Articles

Single-cell transcriptomic and clonotypic characterization of Waldenström macroglobulinemia reveals intra-patient monoclonal diversity with distinct differentiation states

Minghao Dang, Sherif Seif, Maria Acevedo-Calado, Linghua Wang, Janelle Sanchez, Lorenzo Gensini, Hima Bansal, Melody Becnel, Mahmoud Gaballa, Hans Lee, Oren Pasvolsky, Krina Patel, Donna Weber, Jing Christine Ye, Robert Orlowski, Sheeba Thomas

Blood (2025) 146 (Supplement 1): 460.

https://doi.org/10.1182/blood-2025-460

Published: 2025

Journal Articles

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2025-4012

Published: 2025

Journal Articles

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Jatin J. Shah, MD, Lei Feng, MS, Sheeba K. Thomas, MD, Donna Weber, MD, Michael Wang, MD, Elisabet E. Manasanch, MD, Kathleen Mendoza, RN, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 376.

https://doi.org/10.1182/blood.V126.23.376.376

Published: 2015

Journal Articles

Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Jatin J. Shah, MD, Lei Feng, MS, Donna Weber, MD, Sheeba K Thomas, MD, Michael Wang, MD, Francesco Turturro, MD, Muzaffar H. Qazilbash, MD, Nina Shah, MD, Qaiser Bashir, MD, Uday R. Popat, MD, Elisabet E. Manasanch, MD, Silvia C Munoz, RN, Ashley Landry, RN, Kathleen Mendoza, RN, Yago Nieto, MD PhD, Richard E. Champlin, MD, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 3155.

https://doi.org/10.1182/blood.V126.23.3155.3155

Published: 2015

Journal Articles

Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant

Koji Sasaki, MD, Nina Shah, MD, Qaiser Bashir, MD, Chitra M. Hosing, MD, Uday R. Popat, MD, Yago Nieto, MD PhD, Simrit Parmar, MD, Jatin J. Shah, MD, Donna Weber, MD, Daniel Weissinger, Sheeba K. Thomas, MD, Robert Z. Orlowski, MD PhD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2015) 126 (23): 3194.

https://doi.org/10.1182/blood.V126.23.3194.3194

Published: 2015

Journal Articles

Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Jatin J. Shah, MD, Lei Feng, MS, Elisabet E. Manasanch, MD, Donna Weber, MD, Sheeba K Thomas, MD, Francesco Turturro, MD, Nina Shah, MD, Uday R. Popat, MD, Yago Nieto, MD PhD, Qaiser Bashir, MD, Silvia C Munoz, RN, Ashley Landry, RN, Kathleen Mendoza, RN, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 187.

https://doi.org/10.1182/blood.V126.23.187.187

Published: 2015

Journal Articles

Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Catherine M Claussen, MS, Tammy Chuang, Jatin Shah, MD, Hans Lee, MD, Nina Shah, MD, Krina K Patel, Qaiser Bashir, MD, Simrit Parmar, MD, Sheeba Thomas, MD, Muzaffar Qazilbash, MD, Richard Eric Davis, MD, Sattva S. Neelapu, MD, Donna Weber, MD, Robert Z. Orlowski, PhD, MD, Lei Feng, MS, Elisabet E. Manasanch, MD

Blood (2015) 126 (23): 5390.

https://doi.org/10.1182/blood.V126.23.5390.5390

Published: 2015

Journal Articles

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

Paul G. Richardson, MD, Melissa Alsina, MD, Donna Weber, MD, Steven E. Coutre, MD, Sagar Lonial, MD, Cristina Gasparetto, MD, Sutapa Mukhopadhyay, PhD, Michael Ondovik, PharmD, MBA, Mahmudul Khan, PhD, Carole Paley, MD, Robert Schlossman, MD

Blood (2012) 120 (21): 1852.

https://doi.org/10.1182/blood.V120.21.1852.1852

Published: 2012

Journal Articles

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Sagar Lonial, MD, Adam Cohen, Jeffrey Zonder, MD, William I Benzinger, MD, Jonathan L. Kaufman, MD, Robert Z. Orlowski, MD, PhD, R. Donald Harvey, PharmD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Duncan Walker, PhD, Brandi Hilder, PhD, Ann Ptaszynski, Jatin J Shah, MD

Blood (2011) 118 (21): 2935.

https://doi.org/10.1182/blood.V118.21.2935.2935

Published: 2011

Journal Articles

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Jatin J Shah, MD, Jeffrey Zonder, MD, Adam Cohen, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Jonathan L. Kaufman, MD, R. Donald Harvey, PharmD, Duncan Walker, PhD, Kevin Litwiler, PhD, Sharon Karan, Brandi Hilder, Ann Marie Ptaszynski, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 1860.

https://doi.org/10.1182/blood.V118.21.1860.1860

Published: 2011

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma.

Qaiser Bashir, MD, Wei Wei, Alexandre Chiattone, MD, Gabriela Rondon, MD, Simrit Parmar, M.D., Nina Shah, MD, Ernesto Harold Booc, Dinh Yvonne, Qureshi Sofia, Jatin J Shah, MD, Robert Z. Orlowski, MD, PhD, Donna Weber, MD, Richard Champlin, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD

Blood (2010) 116 (21): 4569.

https://doi.org/10.1182/blood.V116.21.4569.4569

Published: 2010

Journal Articles

Autologous Hematopoietic Cell Transplantation In Multiple Myeloma Patients Age 70 Years and Older.

Blood (2010) 116 (21): 4576.

https://doi.org/10.1182/blood.V116.21.4576.4576

Published: 2010

Journal Articles

High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis

Simrit Parmar, M.D., Mubeen Khan, Gabriela Rondon, MD, Nina Shah, MD, Qaiser Bashir, MD, Shawndeep Tung, MD, Jatin J Shah, MD, Donna Weber, MD, Robert Z. Orlowski, MD, PhD, Sergio Giralt, MD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2010) 116 (21): 1350.

https://doi.org/10.1182/blood.V116.21.1350.1350

Published: 2010

Journal Articles

Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

Jatin J Shah, MD, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, MD, Michael Wang, MD, Sheeba Thomas, MD, Muzaffar H. Qazilbash, MD, Simrit Parmar, M.D., Nina Shah, MD, Qaiser Bashir, MD, Uday Popat, MD, Donna Weber, MD

Blood (2010) 116 (21): 1948.

https://doi.org/10.1182/blood.V116.21.1948.1948

Published: 2010

Journal Articles

A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population

Paul Richardson, MD, Donna Weber, MD, Constantine S. Mitsiades, MD, PhD, Meletios A. Dimopoulos, MD, Jean-Luc Harousseau, MD, Jennifer Houp, Thorsten Graef, MD, PhD, Christine K Gause, Catriona Byrne, Kenneth C. Anderson, MD, David Siegel, MD, PhD

Blood (2010) 116 (21): 1951.

https://doi.org/10.1182/blood.V116.21.1951.1951

Published: 2010

Journal Articles

A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma

Jatin J Shah, MD, Jeffrey A. Zonder, MD, Adam Cohen, Donna Weber, MD, Sheeba Thomas, MD, Michael Wang, MD, Jonathan L. Kaufman, MD, Steven Michael Burt, Duncan Walker, Burgess Freeman, Selena Armistead Rush, BS, Ann Ptaszynski, Robert Z. Orlowski, MD, PhD, Sagar Lonial, MD

Blood (2010) 116 (21): 1959.

https://doi.org/10.1182/blood.V116.21.1959.1959

Published: 2010

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia

Single-cell transcriptomic and clonotypic characterization of Waldenström macroglobulinemia reveals intra-patient monoclonal diversity with distinct differentiation states

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant

Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma.

Autologous Hematopoietic Cell Transplantation In Multiple Myeloma Patients Age 70 Years and Older.

High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis

Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population

A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only